Statin use may lower risk of hepatocellular carcinoma

  • Islam MM & al.
  • Cancers (Basel)
  • 13 Mar 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statin use was significantly associated with reductions in the risk of hepatocellular cancer (HCC).
  • Risk reduction was greater in patients with diabetes and liver cirrhosis.

Why this matters

  • Findings provide additional evidence supporting the beneficial inhibitory effect of statins on HCC incidence.

Study design

  • 24 observational studies involving 59,073 patients with HCC met eligibility criteria after a search across PubMed, EMBASE and other databases.
  • Funding: The Ministry of Education and Science and Technology.

Key results

  • Statin users vs nonusers were at lower risk of HCC development (risk ratio [RR], 0.54; 95% CI, 0.47-0.61; I2=84.39%).
  • In the secondary analysis, statin use vs no use was associated with a reduced risk of HCC in patients:
    • with (RR, 0.44; 95% CI, 0.28-0.70) and without (RR, 0.58; 95% CI, 0.48-0.69) diabetes mellitus;
    • with (RR, 0.36; 95% CI, 0.30-0.42) and without (RR, 0.50; 95% CI, 0.35-0.71) liver cirrhosis; and
    • antiviral therapy (RR, 0.21; 95% CI, 0.08-0.59).
  • In the subgroup analysis, risk reduction was greater with:
    • fluvastatin (RR 0.41, 95% CI: 0.25–0.66);
    • lovastatin (RR 0.43, 95% CI: 0.21–0.86);
    • rosuvastatin (RR 0.47, 95% CI: 0.26–0.84).
  • Higher cumulative doses of statins use were associated with greater risk reductions vs lower cumulative doses of statins.

Limitations

  • Heterogeneity among studies.
  • Risk of potential confounding.